June 1, 2015 / 10:03 PM / 3 years ago

Mylan says Teva's stake buy violates U.S. anti-trust rules

(Reuters) - Mylan NV (MYL.O) said Teva Pharmaceutical Industries Ltd (TEVA.TA) (TEVA.N), which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake.

Teva disclosed a 1.35 percent stake in Mylan last week.

"We consider Teva's stakebuilding as a further indication of its intention to meddle with our business, strategy and mission while remaining unclear as to its actual intentions," Mylan said in a letter addressed to Teva's chief executive, Erez Vigodman.(1.usa.gov/1Q0SxgC)

Mylan did not clarify which anti-trust rule Teva violated.

    The two companies were not immediately available for comment.

    Mylan said on Monday there was still no clarity whether Teva would make a formal offer, almost six weeks since Teva’s offer for about $40 billion.

    Reporting by Anjali Rao Koppala in Bengaluru; Editing by Maju Samuel

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below